GLP1R and kidney disorder: The uptake of the glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors (SGLT2i), classes of blood glucose-lowering therapies with glucose-independent benefits for renal disease, especially SGLT2i [43], was relatively low in the FDS2 cohort (<5% in each case at the end of the follow-up period) given that they were first introduced into Australia when the study was in progress.